Genentech gives MR a psychodynamic focus

Share this article:
Laura Sullivan
Laura Sullivan

Genentech is thinking outside the traditional focus group to better understand patients which, in turn, is helping address adherence and brand preference.

“Pharma companies are drowning in data but starving in insight,” said Laura Sullivan, group manager of patient insights, Genentech, at the Pharmaceutical Marketing Research Group (PMRG) 2012 Annual National Conference in Orlando, FL, held in late March.

Since the “non-conscious” plays such a big role, “we need to access the emotional brain without giving consciousness to the subject that that's what we are trying to do,” she said.

Genentech partnered with social science agency Brandtrust to adopt advanced visualization and psychodynamic research techniques to find out why patients are not taking Pulmo­zyme (cystic fibrosis) as prescribed and, for Tamiflu, to gain insights on what makes patients take action quickly. Researchers conduct interviews with respondents, recruited behaviorally, and interviewers have no pre-communication with the client and so are blind to study objectives.

Three key insights emerged:

• The way a product makes a person feel emotionally is greater than any physical benefit;

• There's a good side to being sick (sickness is patients' sanction time); and

• “If you give [patients] permission to skip the ritual…they are more likely to take [the medicine],” Sullivan said.

The technique “is moving the needle on these brands,” she said. “The new Tamiflu DTC ad campaign all started with this project and these insights.” But, Sullivan acknowledged, it can be a hard sell internally.
Share this article:

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.